Through research on breast cancer tissues and cells, researchers have found that approximately 30% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers exhibit ecDNA HER2 amplification and that this ecDNA carrying the HER2 gene is relatively conserved among resistant tumours, regardless of the resistance mechanism. This evidence concerns the gene ERBB2 and breast cancer.